HRP20000400B1 - Transmucosal formulations of levosimendal - Google Patents

Transmucosal formulations of levosimendal

Info

Publication number
HRP20000400B1
HRP20000400B1 HR20000400A HRP20000400A HRP20000400B1 HR P20000400 B1 HRP20000400 B1 HR P20000400B1 HR 20000400 A HR20000400 A HR 20000400A HR P20000400 A HRP20000400 A HR P20000400A HR P20000400 B1 HRP20000400 B1 HR P20000400B1
Authority
HR
Croatia
Prior art keywords
levosimendal
transmucosal formulations
pharmaceutically acceptable
transmucosal
formulations
Prior art date
Application number
HR20000400A
Other languages
English (en)
Croatian (hr)
Inventor
Kurkela Kauko
Marvola Martti
Larma Ilkka
Virtanen Raimo
Karlsson Marianne
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20000400A2 publication Critical patent/HRP20000400A2/hr
Publication of HRP20000400B1 publication Critical patent/HRP20000400B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Paper (AREA)
  • Air Bags (AREA)
  • Luminescent Compositions (AREA)
HR20000400A 1997-12-19 2000-06-16 Transmucosal formulations of levosimendal HRP20000400B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI974578A FI974578A (fi) 1997-12-19 1997-12-19 Menetelmä levosimendaanin antamiseksi
PCT/FI1998/000977 WO1999032081A1 (en) 1997-12-19 1998-12-11 Transmucosal formulations of levosimendan

Publications (2)

Publication Number Publication Date
HRP20000400A2 HRP20000400A2 (en) 2000-12-31
HRP20000400B1 true HRP20000400B1 (en) 2009-06-30

Family

ID=8550178

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000400A HRP20000400B1 (en) 1997-12-19 2000-06-16 Transmucosal formulations of levosimendal

Country Status (26)

Country Link
US (1) US6399610B1 (hu)
EP (1) EP1052973B1 (hu)
JP (1) JP2001526205A (hu)
KR (1) KR100753689B1 (hu)
AT (1) ATE215358T1 (hu)
AU (1) AU738082B2 (hu)
BR (1) BR9813641A (hu)
CA (1) CA2313618C (hu)
CZ (1) CZ296693B6 (hu)
DE (1) DE69804678T2 (hu)
DK (1) DK1052973T3 (hu)
EA (1) EA002197B1 (hu)
EE (1) EE04330B1 (hu)
ES (1) ES2175827T3 (hu)
FI (1) FI974578A (hu)
HR (1) HRP20000400B1 (hu)
HU (1) HU226736B1 (hu)
IL (1) IL136415A (hu)
NO (1) NO320050B1 (hu)
NZ (1) NZ504806A (hu)
PL (1) PL191868B1 (hu)
PT (1) PT1052973E (hu)
RS (1) RS49889B (hu)
SK (1) SK284838B6 (hu)
WO (1) WO1999032081A1 (hu)
ZA (1) ZA9811405B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980901A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
FI20040674A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1848270B1 (en) * 2005-02-17 2014-05-21 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
WO2006087420A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
CN101516426A (zh) 2006-09-27 2009-08-26 尼克诺姆股份公司 定向用途
US11523986B2 (en) * 2019-03-22 2022-12-13 Dbbh, Llc Intranasally administered antihistamines and uses thereof
WO2021001601A1 (en) * 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012135A1 (en) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
WO1998001111A1 (en) * 1996-07-05 1998-01-15 Orion-Yhtymä Oy Transdermal compositions containing levosimendan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012135A1 (en) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
WO1998001111A1 (en) * 1996-07-05 1998-01-15 Orion-Yhtymä Oy Transdermal compositions containing levosimendan

Also Published As

Publication number Publication date
HUP0100452A3 (en) 2002-03-28
IL136415A (en) 2005-03-20
ZA9811405B (en) 1999-06-11
AU1565699A (en) 1999-07-12
EA002197B1 (ru) 2002-02-28
FI974578A0 (fi) 1997-12-19
CZ296693B6 (cs) 2006-05-17
CA2313618C (en) 2008-02-05
DE69804678D1 (de) 2002-05-08
EE04330B1 (et) 2004-08-16
WO1999032081A1 (en) 1999-07-01
NO20003059L (no) 2000-06-14
NO20003059D0 (no) 2000-06-14
EP1052973A1 (en) 2000-11-22
ATE215358T1 (de) 2002-04-15
YU36900A (sh) 2003-02-28
PL191868B1 (pl) 2006-07-31
DE69804678T2 (de) 2002-11-21
HUP0100452A2 (hu) 2002-02-28
CZ20002155A3 (cs) 2000-11-15
KR100753689B1 (ko) 2007-08-30
KR20010033368A (ko) 2001-04-25
BR9813641A (pt) 2000-10-17
JP2001526205A (ja) 2001-12-18
NO320050B1 (no) 2005-10-17
EP1052973B1 (en) 2002-04-03
PT1052973E (pt) 2002-09-30
RS49889B (sr) 2008-08-07
NZ504806A (en) 2001-09-28
ES2175827T3 (es) 2002-11-16
AU738082B2 (en) 2001-09-06
HU226736B1 (en) 2009-08-28
CA2313618A1 (en) 1999-07-01
SK284838B6 (sk) 2005-12-01
IL136415A0 (en) 2001-06-14
FI974578A (fi) 1999-06-20
EE200000368A (et) 2001-10-15
US6399610B1 (en) 2002-06-04
DK1052973T3 (da) 2002-04-29
SK9062000A3 (en) 2000-12-11
HRP20000400A2 (en) 2000-12-31
EA200000686A1 (ru) 2000-12-25
PL341202A1 (en) 2001-03-26

Similar Documents

Publication Publication Date Title
TR199501447A2 (tr) Oral bilesimler.
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
DZ2026A1 (fr) Compositions vaccinantes.
DZ2055A1 (fr) Compositions vaccinantes.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
TR199800375A3 (tr) Selant kompozisyonlari.
YU15499A (sh) Olanzapin dihidrat d
DZ1835A1 (fr) Nouvelles formulations.
MA25279A1 (fr) Compositions rafraichissantes.
NO993096D0 (no) Orale cyklosporinformuleringer
ITRM940002A0 (it) Composizione orale.
DZ2283A1 (fr) Composition de vaccin.
TR199501650A2 (tr) Agiz bilesimleri.
DK0966299T3 (da) Hidtil ukendte orale formuleringer af calcitonin.
DK1023035T3 (da) Mundplejemiddel
HRP20000400B1 (en) Transmucosal formulations of levosimendal
ATE263550T1 (de) Orale cyclosporinformulierungen
ID23772A (id) Komposisi-komposisi melalui mulut
TR199501645A2 (tr) Agiz bilesimleri.
DE69300492T2 (de) Orale Zusammensetzung.
TR199700147A2 (tr) Mikrop öldürücü terkip.
TR199501649A2 (tr) Agiz bilesimleri.
DK0866709T3 (da) 1,2,4-benzotriazinoxidformuleringer
TR199501651A2 (tr) Agiz bilesimleri.
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20091126

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20101212